An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease
about
Neuroprotection by pharmacologic blockade of the GAPDH death cascadeNitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of CocaineTherapeutic neuroprotective agents for amyotrophic lateral sclerosisA computational strategy to select optimized protein targets for drug development toward the control of cancer diseasesEthanol and Acetaminophen Synergistically Induce Hepatic Aggregation and TCH346-Insensitive Nuclear Translocation of GAPDHProtein-L-isoaspartate (D-aspartate) O-methyltransferase protects cardiomyocytes against hypoxia induced apoptosis through inhibiting proapoptotic kinase Mst1New insights into mitochondrial structure during cell death.Behavioral effects of cocaine mediated by nitric oxide-GAPDH transcriptional signaling.Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer questionALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophyFunctional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.Current and emerging treatments for amyotrophic lateral sclerosis.FeCl3 catalysed 7-membered ring formation in a single pot: a new route to indole-fused oxepines/azepines and their cytotoxic activity.FeCl3-catalyzed synthesis of functionally diverse dibenzo[b,f]oxepines and benzo[b]oxepines via alkyne-aldehyde metathesis.
P2860
Q24545207-71109274-DD66-4CFB-A9E4-5DDD15412D47Q27009552-035F8DFB-B5B9-4119-A203-0AC2375CD901Q27015029-0DAAD24D-9F0C-4A9A-AFF3-C1F123BB2951Q28543105-35470E52-5882-4592-94DE-E2E6A47A737FQ28553472-5DC9FD2C-7EF5-4FC4-99DD-F6FF29B5F1FBQ28569469-985861FC-777B-4375-9C1E-87B10FB056E3Q30480195-17673173-A2D3-4FF8-97D0-C8E5F5C82991Q30580057-95499536-60E0-4CEF-B9D1-7F09F331C6FDQ34459681-715B4B8E-E5F6-4F56-961E-B74768A557ACQ34554820-F62975E8-64FA-4D5C-A655-39A22DBFCFBCQ34769964-44D8F111-996F-4B2D-9976-1AB6E4160D3EQ37578490-3CAE82F9-FB04-4BDC-80DB-53F0B0C465BFQ38573829-F4C19530-DDA0-4A17-8D68-776167448C40Q42685032-7AF5EEA5-160A-4B0D-8D71-CD5268456150Q53297663-76B60876-5FBC-4603-A620-7B612075DB6BQ54617108-3D9C1F63-DE99-4A5F-B446-EAC605060DEB
P2860
An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
An orally active anti-apoptoti ...... al model of motoneuron disease
@ast
An orally active anti-apoptoti ...... al model of motoneuron disease
@en
type
label
An orally active anti-apoptoti ...... al model of motoneuron disease
@ast
An orally active anti-apoptoti ...... al model of motoneuron disease
@en
prefLabel
An orally active anti-apoptoti ...... al model of motoneuron disease
@ast
An orally active anti-apoptoti ...... al model of motoneuron disease
@en
P2093
P2860
P356
P1476
An orally active anti-apoptoti ...... al model of motoneuron disease
@en
P2093
D Perrelet
L Mattenberger
P C Waldmeier
P2860
P304
P356
10.1038/SJ.BJP.0703633
P407
P577
2000-10-01T00:00:00Z